资金逢跌加仓恒生创新药ETF（520500）！标的指数今日起获得南向互联互通交易资格

Group 1 - The innovative drug sector is experiencing volatility, but market enthusiasm for investment remains strong, as evidenced by the high trading volume of the Hang Seng Innovative Drug ETF (520500) [1] - The Hang Seng Innovative Drug ETF has seen a continuous inflow of funds for three consecutive trading days, with its latest share count and scale reaching 597 million shares and 1.155 billion yuan, respectively, marking a growth of over 136% in the last three months [1][2] - The Hang Seng Innovative Drug Index has been revised to exclude CXO industry companies, focusing on pharmaceuticals and biotechnology, which enhances the index's purity and aligns it more closely with core industry drivers [1][2] Group 2 - The Hang Seng Innovative Drug Index now consists of 29 constituent stocks, all from Hong Kong, showcasing high-growth potential innovative drug companies, which adds to its investment value [2] - Recent updates from the National Healthcare Security Administration indicate that several newly included domestic innovative drugs are rapidly entering hospitals, suggesting future catalysts for the innovative drug sector [2] - The Hang Seng Innovative Drug ETF (520500) is managed by Huatai-PB Fund, which has over 18 years of ETF operation experience, further enhancing investor confidence [2][3] Group 3 - The innovative drug sector is showing signs of fundamental improvement driven by innovation and policy support, with the Hang Seng Innovative Drug Index's purity and growth potential expected to increase further [3] - The liquidity and T+0 trading support of the Hang Seng Innovative Drug ETF (520500) make it an attractive option for investors looking to capitalize on the accelerating opportunities in the innovative drug sector [3]